
OKUR Stock Forecast & Price Target
OKUR Analyst Ratings
Bulls say
OnKure Therapeutics Inc demonstrated a narrower-than-expected net loss of $1.14 per share in 2Q25, indicating better financial performance relative to prior estimates. The company's lead product candidate, OKI-219, exhibited a favorable safety profile, being well-tolerated across all dose levels without any severe adverse events, thus underscoring the potential for successful future development. These factors collectively suggest a strong foundation for the company's growth and advancement in precision cancer therapies, which are targeting underserved treatment areas.
Bears say
OnKure Therapeutics is projecting a significant annual net loss of $4.56 per share for the year 2025, an improvement from its previous estimate of $4.75 per share, yet still indicative of the company's ongoing financial struggles. The company faces multiple risks, including potential negative clinical results associated with its lead asset, OKI-219, and delays in advancing its pipeline candidates, which could further complicate its path to regulatory approvals. Additionally, there are concerns regarding competitive pressures from other therapies in the market that could hinder OnKure's growth prospects, along with the risk of long-term shareholder dilution.
This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OKUR Analyst Forecast & Price Prediction
Start investing in OKUR
Order type
Buy in
Order amount
Est. shares
0 shares